Skip to main content
Premium Trial:

Request an Annual Quote

IonGate, LIVC to Co-Develop, Market Ion Channel Screening Technology

NEW YORK (GenomeWeb News) - IonGate Biosciences and LIVC Technologies, both located in Frankfurt am Main, Germany, said today that they plan to co-develop and co-market LIVC’s technology for ion channel screening.
 
The technology, Light-Induced Voltage Clamp, uses light induction to measure voltage-activated ion channels. According to the companies, the method enables fast, high-throughput screening of voltage-activated ion channels and provides higher-quality data than current methods.
 
The companies said that the approach is applicable for finding new compounds that act directly on voltage-activated ion channels and determining their method of action.
 
IonGate specializes in transporter screening technology and markets the SURFE2R workstation. It was founded in 2000.
 
LIVC Technologies was founded earlier this year in order to commercialize the LIVC technology.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.